News

April 15, 2022

Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Press Release
Abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022

https://zsjnm.huc.edu/analytical/introduction-of-assignment/2/ see url what tier is levitra https://reflectionsbodysolutions.com/doctor/711-viagra-pills/82/ computer science thesis word count comprar viagra francia follow site https://moorelifeurgentcare.com/edtreatment/levitra-n1/84/ se tomar anafranil viagra https://easternpropane.com/savings/blue-cross-coverage-viagra/87/ premarin with methyltestosterone go site painting and photography essay https://familyfeastandferia.com/reviews/in-management-thesis/94/ watch expository essay on rosa parks is generic viagra from canada real daily viagra safe how long effects of cialis https://samponline.org/blacklives/essay-managerial-accounting/27/ real mature seduction https://switzerlanddanceschool.com/case/essay-about-tutoring/8/ https://businesswomanguide.org/capstone/solar-system-essay-questions-for-kids/22/ source buy essays cheap custom essay writing https://zsjnm.huc.edu/analytical/hamitic-thesis/2/ follow site viagra tablet information online prescription for viagra lemon https://zacharyelementary.org/presentation/introduction-and-conclusion-of-an-essay/30/ prednisone interaction with synthroid romeo and juliet west side story compare and contrast essay Toronto, Canada, April 14, 2022 —   Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for the 2022 ASCO Annual Meeting and will be published in an online supplement of the Journal of Clinical Oncology following the meeting. ASCO will be held in Chicago from June 3-8, 2022.

This year, ASCO received and reviewed more than 6,000 abstracts for the 2022 ASCO Annual Meeting. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend. Per ASCO’s Embargo & Release Information, abstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 26, 2022.

September 16, 2021

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
Press Release

Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced the presentation of new preclinical data from the Company’s investigational therapy, ACT-903 at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

View Full Press Release
View Poster

August 17, 2021

AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunology therapies based on its proprietary recombinant human Alpha Fetoprotein platform, today announced that its abstract featuring data from the Company’s investigational therapy, ACT-903, has been selected for presentation at the European Society of Medical Oncology (ESMO) Annual Meeting being held virtually September 16-21, 2021.

Details about the abstract selected for poster publication can be found below:

Title: AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
Abstract Number: 523P
Authors: I. Sherman, R. Boohaker, K. Stinson, P. Griffin, W. Hill
Abstracts are under embargo until 5:00 p.m. ET on Sept. 15, 2021.

For more information about the Annual Meeting, please visit: https://www.esmo.org/meetings/esmo-congress-2021

July 21, 2020

Alpha Cancer Technologies to License AbSci’s SoluPro Strain for the Expression of Alpha-Fetoprotein
Press Release

AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers. This license is an expansion of a previous collaboration between the parties that began last year.

Download

October 17, 2017

Study Results of ACT-101 in a Model of Inflammatory Bowel Disease (IBD) Presented at the World Congress of Gastroenterology 2017
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on therapies for patients with autoimmune diseases and cancer, today announced the results of a study of ACT-101 (recombinant human alpha fetoprotein or rhAFP) in the treatment of Inflammatory Bowel Disease (IBD) at the World Congress of Gastroenterology 2017, held in partnership with The American College of Gastroenterology in Orlando, Florida. The study was sponsored by ACT to corroborate published clinical trial results using native human AFP.

Download

June 15, 2017

Alpha Cancer Technologies Inc. Reports Acceptance of the Abstract of Study of ACT-101 in a Model of Inflammatory Bowel Disease to the World Congress of Gastroenterology at ACG 2017
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a pre-clinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.

Download

May 15, 2017

Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 Study Results in Pre-Clinical Model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders
Press Release

Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.

Download

May 28, 2014

PolyTherics and Alpha Cancer Technologies Collaborate to Produce Novel Drug Conjugates to Target Tumours
Press Release

PolyTherics Limited (“PolyTherics”), an Abzena company that provides technologies and services to enable the development of better biopharmaceuticals, today announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”), a Canadian company with a targeted drug delivery platform based on alpha fetoprotein (“AFP”). PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.

Download

March 11, 2014

Alpha Cancer To Test Oncology Game Changer
BioTuesdays

AFP is a carrier protein known for transporting nutrients to rapidly growing fetal cells. Only trace amounts of the protein are found following birth, but importantly, receptors for AFP show up again on cancer cells to help shuttle nutrients to rapidly growing cancer cells.

Read